Pioneering diagnostics
E.g., 20/06/2019
E.g., 20/06/2019
PreviousNext

bioMérieux submits for FDA Clearance of the  BIOFIRE® FILMARRAY® Pneumonia Panel  

19 April, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel....

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

04 April, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation...

2017 Financial Results

28 February, 2018

  • Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:
    • €2,288 million in sales
    • Up 8.8% as reported
  • Strong 12.4% increase in contributive operating income before non-recurring items...

bioMérieux – Fourth-Quarter 2017 Business Review

23 January, 2018

  • Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation:
    • €2,288 million in sales
    • Up 8.8% as reported...

CNES and bioMérieux extend their collaboration on Aquapad, a unique water quality testing tool

15 January, 2018

Monday 15 January in Marcy l’Étoile (near Lyon), Proxima mission astronaut Thomas Pesquet detailed, during a conference, lessons learned from the Aquapad experiment he performed on the International Space Station (ISS). Developed jointly by CNES and bioMérieux, a world leader in ...

CNES and bioMérieux extend their collaboration on Aquapad, a unique water quality testing tool

15 January, 2018

Monday 15 January in Marcy l’Étoile (near Lyon), Proxima mission astronaut Thomas Pesquet detailed, during a conference, lessons learned from the Aquapad experiment he performed on the International Space Station (ISS). Developed jointly by CNES and bioMérieux, a world leader in ...

Alexandre Mérieux appointed Chairman and CEO of bioMérieux

15 December, 2017

The Board of Directors of bioMérieux met today and approved the appointment of Alexandre Mérieux as Chairman and CEO of the Company, taking effect immediately.
After serving as Deputy CEO of bioMérieux for the last...

bioMérieux – Business review for the nine months ended September 30, 2017

18 October, 2017

  • Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation
    • €1,674 million in sales
    • Up 10.8% as reported
  • In microbiology, growth accelerated to nearly 8%
  • Contribution from all regions to the Group's strong...

bioMérieux – First-Half 2017 Results

30 August, 2017

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® MS, its MALDI-TOF1 Mass...

PreviousNext